The clinical efficacy of Shenxiang Suhe Pill administration in posterior circulation ischemic vertigo: A randomized controlled trial

Shenxiang Suhe Pill (SXSHP) is a traditional Chinese medicine (TCM) widely used to treat coronary heart disease. The present study aims to investigate the effect of SXSHP on posterior circulation ischemic (PCI) vertigo. One hundred and twenty patients with PCI vertigo were randomly divided into the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2023-12, Vol.102 (51), p.e36604-e36604
Hauptverfasser: Zhang, Yongjian, Xu, Lin, Wang, Xiaoping, Ma, Jianjun, Song, Xiaping, Lv, Heng, Jin, Luyao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e36604
container_issue 51
container_start_page e36604
container_title Medicine (Baltimore)
container_volume 102
creator Zhang, Yongjian
Xu, Lin
Wang, Xiaoping
Ma, Jianjun
Song, Xiaping
Lv, Heng
Jin, Luyao
description Shenxiang Suhe Pill (SXSHP) is a traditional Chinese medicine (TCM) widely used to treat coronary heart disease. The present study aims to investigate the effect of SXSHP on posterior circulation ischemic (PCI) vertigo. One hundred and twenty patients with PCI vertigo were randomly divided into the control, low-dose, and high-dose groups with 40 patients in each group. The control group was treated with basic Western medicine. The low-dose and high-dose groups were treated with 0.7 g SXSHP once a day in the morning and twice a day in the morning and evening, respectively. The assessments were performed on days 14 and 28. The traditional Chinese medicine symptom score, average blood flow velocity of vertebral artery and basilar artery, blood viscosity, blood lipids, serum C-reactive protein level (CRP), blood routine test, and liver and kidney function were compared before and after treatment among the 3 groups. In the evaluation of the traditional Chinese medicine symptom score, both low-dose and high-dose SXSHP treatments showed higher efficacy than the control group (P = .013). The average blood flow velocity of vertebral artery and basilar artery in the 3 groups showed an upward trend from baseline (P 
doi_str_mv 10.1097/MD.0000000000036604
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10735062</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2905525422</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-a0aefc112cece08b9588c3d5b2c5c494db73043a0d92b88dec95c90385f809683</originalsourceid><addsrcrecordid>eNpdUU1v1TAQtBCIvhZ-ARLykUvK-iuxuaCqpYDUCqSWs-VsnPeMnPhhJxXtuT-cVH0U2r3MSjszu6sh5A2DQwameX9-cgj_StQ1yGdkxZSoK2Vq-ZysALiqGtPIPbJfyk8AJhouX5I9oZmQUMOK3F5uPMUYxoAuUt_3C-I1TT292Pjxd3Djml7MC-d7iJG6bliYZcpuCmmkYaTbVCafQ8oUQ8Y57gYFN34ISK98nsI6faBHNLuxS0O48R3FNE45xbi0Uw4uviIveheLf73DA_Lj9NPl8Zfq7Nvnr8dHZxUKVU-VA-d7ZIyjRw-6NUprFJ1qOSqURnZtI0AKB53hrdadR6PQgNCq12BqLQ7Ix3vf7dwOvkO_nOGi3eYwuHxtkwv28WQMG7tOV5ZBIxTUfHF4t3PI6dfsy2SH5Vcfoxt9movlBpTiSvI7qrinYk6lZN8_7GFg7wK05yf2aYCL6u3_Jz5o_iYm_gCLaZn1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2905525422</pqid></control><display><type>article</type><title>The clinical efficacy of Shenxiang Suhe Pill administration in posterior circulation ischemic vertigo: A randomized controlled trial</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhang, Yongjian ; Xu, Lin ; Wang, Xiaoping ; Ma, Jianjun ; Song, Xiaping ; Lv, Heng ; Jin, Luyao</creator><creatorcontrib>Zhang, Yongjian ; Xu, Lin ; Wang, Xiaoping ; Ma, Jianjun ; Song, Xiaping ; Lv, Heng ; Jin, Luyao</creatorcontrib><description>Shenxiang Suhe Pill (SXSHP) is a traditional Chinese medicine (TCM) widely used to treat coronary heart disease. The present study aims to investigate the effect of SXSHP on posterior circulation ischemic (PCI) vertigo. One hundred and twenty patients with PCI vertigo were randomly divided into the control, low-dose, and high-dose groups with 40 patients in each group. The control group was treated with basic Western medicine. The low-dose and high-dose groups were treated with 0.7 g SXSHP once a day in the morning and twice a day in the morning and evening, respectively. The assessments were performed on days 14 and 28. The traditional Chinese medicine symptom score, average blood flow velocity of vertebral artery and basilar artery, blood viscosity, blood lipids, serum C-reactive protein level (CRP), blood routine test, and liver and kidney function were compared before and after treatment among the 3 groups. In the evaluation of the traditional Chinese medicine symptom score, both low-dose and high-dose SXSHP treatments showed higher efficacy than the control group (P = .013). The average blood flow velocity of vertebral artery and basilar artery in the 3 groups showed an upward trend from baseline (P &lt; .05). The blood viscosity and levels of fibrinogen, hematocrit, and CRP in the 3 groups showed a downward trend from baseline level (P &lt; .05). The levels of total cholesterol, triglycerides, low-density lipoprotein, and CRP in the low-dose group and high-dose group were lower than those in the control group on day 28 (P &lt; .05). There were no significant differences in the routine blood test and liver and kidney function between the low-dose and high-dose groups compared with the baseline values (P &gt; .05). SXSHP effectively improved PCI vertigo by inhibiting blood viscosity, regulating blood lipid levels, anti-inflammation, and improving cerebrovascular blood flow without affecting liver and kidney functions.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000036604</identifier><identifier>PMID: 38134060</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Clinical Trial/Experimental Study ; Coronary Disease - drug therapy ; Drugs, Chinese Herbal - therapeutic use ; Humans ; Ischemia - drug therapy ; Medicine, Chinese Traditional ; Percutaneous Coronary Intervention ; Treatment Outcome ; Vertigo - drug therapy</subject><ispartof>Medicine (Baltimore), 2023-12, Vol.102 (51), p.e36604-e36604</ispartof><rights>Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c356t-a0aefc112cece08b9588c3d5b2c5c494db73043a0d92b88dec95c90385f809683</cites><orcidid>0009-0000-8388-681 ; 0009-0000-8388-681X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10735062/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10735062/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,862,883,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38134060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yongjian</creatorcontrib><creatorcontrib>Xu, Lin</creatorcontrib><creatorcontrib>Wang, Xiaoping</creatorcontrib><creatorcontrib>Ma, Jianjun</creatorcontrib><creatorcontrib>Song, Xiaping</creatorcontrib><creatorcontrib>Lv, Heng</creatorcontrib><creatorcontrib>Jin, Luyao</creatorcontrib><title>The clinical efficacy of Shenxiang Suhe Pill administration in posterior circulation ischemic vertigo: A randomized controlled trial</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Shenxiang Suhe Pill (SXSHP) is a traditional Chinese medicine (TCM) widely used to treat coronary heart disease. The present study aims to investigate the effect of SXSHP on posterior circulation ischemic (PCI) vertigo. One hundred and twenty patients with PCI vertigo were randomly divided into the control, low-dose, and high-dose groups with 40 patients in each group. The control group was treated with basic Western medicine. The low-dose and high-dose groups were treated with 0.7 g SXSHP once a day in the morning and twice a day in the morning and evening, respectively. The assessments were performed on days 14 and 28. The traditional Chinese medicine symptom score, average blood flow velocity of vertebral artery and basilar artery, blood viscosity, blood lipids, serum C-reactive protein level (CRP), blood routine test, and liver and kidney function were compared before and after treatment among the 3 groups. In the evaluation of the traditional Chinese medicine symptom score, both low-dose and high-dose SXSHP treatments showed higher efficacy than the control group (P = .013). The average blood flow velocity of vertebral artery and basilar artery in the 3 groups showed an upward trend from baseline (P &lt; .05). The blood viscosity and levels of fibrinogen, hematocrit, and CRP in the 3 groups showed a downward trend from baseline level (P &lt; .05). The levels of total cholesterol, triglycerides, low-density lipoprotein, and CRP in the low-dose group and high-dose group were lower than those in the control group on day 28 (P &lt; .05). There were no significant differences in the routine blood test and liver and kidney function between the low-dose and high-dose groups compared with the baseline values (P &gt; .05). SXSHP effectively improved PCI vertigo by inhibiting blood viscosity, regulating blood lipid levels, anti-inflammation, and improving cerebrovascular blood flow without affecting liver and kidney functions.</description><subject>Clinical Trial/Experimental Study</subject><subject>Coronary Disease - drug therapy</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Humans</subject><subject>Ischemia - drug therapy</subject><subject>Medicine, Chinese Traditional</subject><subject>Percutaneous Coronary Intervention</subject><subject>Treatment Outcome</subject><subject>Vertigo - drug therapy</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUU1v1TAQtBCIvhZ-ARLykUvK-iuxuaCqpYDUCqSWs-VsnPeMnPhhJxXtuT-cVH0U2r3MSjszu6sh5A2DQwameX9-cgj_StQ1yGdkxZSoK2Vq-ZysALiqGtPIPbJfyk8AJhouX5I9oZmQUMOK3F5uPMUYxoAuUt_3C-I1TT292Pjxd3Djml7MC-d7iJG6bliYZcpuCmmkYaTbVCafQ8oUQ8Y57gYFN34ISK98nsI6faBHNLuxS0O48R3FNE45xbi0Uw4uviIveheLf73DA_Lj9NPl8Zfq7Nvnr8dHZxUKVU-VA-d7ZIyjRw-6NUprFJ1qOSqURnZtI0AKB53hrdadR6PQgNCq12BqLQ7Ix3vf7dwOvkO_nOGi3eYwuHxtkwv28WQMG7tOV5ZBIxTUfHF4t3PI6dfsy2SH5Vcfoxt9movlBpTiSvI7qrinYk6lZN8_7GFg7wK05yf2aYCL6u3_Jz5o_iYm_gCLaZn1</recordid><startdate>20231222</startdate><enddate>20231222</enddate><creator>Zhang, Yongjian</creator><creator>Xu, Lin</creator><creator>Wang, Xiaoping</creator><creator>Ma, Jianjun</creator><creator>Song, Xiaping</creator><creator>Lv, Heng</creator><creator>Jin, Luyao</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0000-8388-681</orcidid><orcidid>https://orcid.org/0009-0000-8388-681X</orcidid></search><sort><creationdate>20231222</creationdate><title>The clinical efficacy of Shenxiang Suhe Pill administration in posterior circulation ischemic vertigo: A randomized controlled trial</title><author>Zhang, Yongjian ; Xu, Lin ; Wang, Xiaoping ; Ma, Jianjun ; Song, Xiaping ; Lv, Heng ; Jin, Luyao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-a0aefc112cece08b9588c3d5b2c5c494db73043a0d92b88dec95c90385f809683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Clinical Trial/Experimental Study</topic><topic>Coronary Disease - drug therapy</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Humans</topic><topic>Ischemia - drug therapy</topic><topic>Medicine, Chinese Traditional</topic><topic>Percutaneous Coronary Intervention</topic><topic>Treatment Outcome</topic><topic>Vertigo - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yongjian</creatorcontrib><creatorcontrib>Xu, Lin</creatorcontrib><creatorcontrib>Wang, Xiaoping</creatorcontrib><creatorcontrib>Ma, Jianjun</creatorcontrib><creatorcontrib>Song, Xiaping</creatorcontrib><creatorcontrib>Lv, Heng</creatorcontrib><creatorcontrib>Jin, Luyao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yongjian</au><au>Xu, Lin</au><au>Wang, Xiaoping</au><au>Ma, Jianjun</au><au>Song, Xiaping</au><au>Lv, Heng</au><au>Jin, Luyao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical efficacy of Shenxiang Suhe Pill administration in posterior circulation ischemic vertigo: A randomized controlled trial</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2023-12-22</date><risdate>2023</risdate><volume>102</volume><issue>51</issue><spage>e36604</spage><epage>e36604</epage><pages>e36604-e36604</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Shenxiang Suhe Pill (SXSHP) is a traditional Chinese medicine (TCM) widely used to treat coronary heart disease. The present study aims to investigate the effect of SXSHP on posterior circulation ischemic (PCI) vertigo. One hundred and twenty patients with PCI vertigo were randomly divided into the control, low-dose, and high-dose groups with 40 patients in each group. The control group was treated with basic Western medicine. The low-dose and high-dose groups were treated with 0.7 g SXSHP once a day in the morning and twice a day in the morning and evening, respectively. The assessments were performed on days 14 and 28. The traditional Chinese medicine symptom score, average blood flow velocity of vertebral artery and basilar artery, blood viscosity, blood lipids, serum C-reactive protein level (CRP), blood routine test, and liver and kidney function were compared before and after treatment among the 3 groups. In the evaluation of the traditional Chinese medicine symptom score, both low-dose and high-dose SXSHP treatments showed higher efficacy than the control group (P = .013). The average blood flow velocity of vertebral artery and basilar artery in the 3 groups showed an upward trend from baseline (P &lt; .05). The blood viscosity and levels of fibrinogen, hematocrit, and CRP in the 3 groups showed a downward trend from baseline level (P &lt; .05). The levels of total cholesterol, triglycerides, low-density lipoprotein, and CRP in the low-dose group and high-dose group were lower than those in the control group on day 28 (P &lt; .05). There were no significant differences in the routine blood test and liver and kidney function between the low-dose and high-dose groups compared with the baseline values (P &gt; .05). SXSHP effectively improved PCI vertigo by inhibiting blood viscosity, regulating blood lipid levels, anti-inflammation, and improving cerebrovascular blood flow without affecting liver and kidney functions.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>38134060</pmid><doi>10.1097/MD.0000000000036604</doi><orcidid>https://orcid.org/0009-0000-8388-681</orcidid><orcidid>https://orcid.org/0009-0000-8388-681X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2023-12, Vol.102 (51), p.e36604-e36604
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10735062
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection
subjects Clinical Trial/Experimental Study
Coronary Disease - drug therapy
Drugs, Chinese Herbal - therapeutic use
Humans
Ischemia - drug therapy
Medicine, Chinese Traditional
Percutaneous Coronary Intervention
Treatment Outcome
Vertigo - drug therapy
title The clinical efficacy of Shenxiang Suhe Pill administration in posterior circulation ischemic vertigo: A randomized controlled trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T05%3A52%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20efficacy%20of%20Shenxiang%20Suhe%20Pill%20administration%20in%20posterior%20circulation%20ischemic%20vertigo:%20A%20randomized%20controlled%20trial&rft.jtitle=Medicine%20(Baltimore)&rft.au=Zhang,%20Yongjian&rft.date=2023-12-22&rft.volume=102&rft.issue=51&rft.spage=e36604&rft.epage=e36604&rft.pages=e36604-e36604&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000036604&rft_dat=%3Cproquest_pubme%3E2905525422%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2905525422&rft_id=info:pmid/38134060&rfr_iscdi=true